Efficacy and Safety of Donidalorsen for Hereditary Angioedema

A randomized, controlled trial of donidalorsen, which targets prekallikrein mRNA, in patients with hereditary angioedema showed a lower attack rate in the treatment groups than in the placebo group.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology